Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates

Vaccine

Volumn 26, Issue 27-28, 2008, Pages 3497-3506

  Fine, Donald L ^a   Roberts, Brian A ^b   Terpening, Sara J ^a   Mott, Jason ^c   Vasconcelos, Daphne ^c   House, Robert V ^a  

^a A CSC Company   (United States)

^b U S ARMY   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Nonhuman primates; Vaccines; Venezuelan equine encephalitis virus (VEEV)

Indexed keywords

LIVE VACCINE; LIVER ENZYME; NEUTRALIZING ANTIBODY; TC 38; V3526;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; DONKEY; DRUG SCREENING; ENCEPHALOMYELITIS; FEMALE; GLIOSIS; HISTOPATHOLOGY; IMMUNOGENICITY; INOCULATION; MALE; NEUROLOGIC DISEASE; NONHUMAN; PARALYSIS; PARESIS; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; SERODIAGNOSIS; SPINAL CORD; VENEZUELA; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIREMIA; VIRUS CULTURE; VIRUS VIRULENCE;

ANIMALS; ANTIBODIES, VIRAL; BODY TEMPERATURE; BODY WEIGHT; BRAIN; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; LIVER FUNCTION TESTS; MACACA MULATTA; MALE; NERVOUS SYSTEM DISEASES; NEUTRALIZATION TESTS; SEVERITY OF ILLNESS INDEX; SPINAL CORD; TIME FACTORS; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA;

EID: 44749083368     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.044     Document Type: Article

References (20)

1. Weaver S.C., Ferro C., Barriera R., Boshell J., and Navarro J. Venezuelan equine encephalitis. Ann Rev Entomol 49 (2004) 141-174
2. Smith J.F., Davis K., Hart M.K., Ludwig G.M., McClain D.J., Parker M.D., et al. In: Sidwell R.V., Takafuji E.T., and Franz D.R. (Eds). Medical aspects of chemical and biological warfare (1997) 561-589 [chapter 28]
3. Johnson K.M., and Martin D.H. Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18 (1974) 79-116
4. Weaver S., and Barrett A. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat Rev Microbiol 2 (2004) 789-801
5. de Mucha-Macias J., and Sanchez-Spindola I. Two human cases of laboratory infection with Mucambo virus. Am J Trop Med Hyg 14 (1965) 475-478
6. Dietz W.J., Peralta P.H., and Johnson K. Ten clinical cases of human infection with Venezuelan equine encephalomyelitis virus, subtype I-D. Am J Trop Med Hyg 28 (1979) 329-334
7. Charles P.C., Walters E., Margolis F., and Johnson R.E. Mechanisms of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208 (1995) 662-671
8. Davis N., Brown K., Greenwald G., Zajac A., Zacny V., Smith J., et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology 212 (1995) 102-110
9. Davis N., Powell N., Greenwald G., Willis L., Johnson B., Smith J., et al. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183 (1991) 20-31
10. Davis N., Willis L., Smith J., and Johnston R. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of viable deletion mutant. Virology 171 (1989) 189-204
11. Pratt W., Davis N., Johnston R., and Smith J. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 21 (2003) 3854-3862
12. Hart M., Caswell-Stephan K., Bakken R., Tammariello R., Pratt W., Davis N., et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18 (2000) 3067-3075
13. Ludwig G., Turell M., Vogel P., Kondig J., Kell W., Smith J., et al. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am J Trop Med Hyg 64 (2001) 49-55
14. Steele K., Davis K., Stephan K., Kell W., Vogel P., and Hart M. Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/NeN and BALB/c mice. Vet Pathol 35 (1998) 386-397
15. Turell M., Ludwig G., Kondig J., and Smith J. Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates. Am J Trop Med Hyg 60 (1999) 1041-1044
16. Fine D.L., Roberts B.A., Teehee M.L., Terpening S.J., Kelly C.L.H., Raetz J.J., et al. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses. Vaccine 25 (2007) 1868-1876
17. Monath T., Calisher C., Davis M., Bowen G., and White J. Experimental studies of rhesus monkeys infected with epizootic and enzootic subtypes of Venezuelan equine encephalitis virus. J Infect Dis 129 (1974) 194-200
18. Berge T.O., Banks I.S., and Tigertt W.D. Attenuatioin of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells. Am J Hyg 73 (1961) 209-218
19. Wang E., Petrakova O., Adams A.P., Aquilar P.V., Kang W., Paessler S., et al. Chimeric sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice. Vaccine 25 43 (2007) 7573-7581
20. Hart M.K., Lind C., Bakken R., Robertson M., Tammariello R., and Ludwig G.M. Onset and duration of protective immunity to IA/B and IE strains of Venezuelan equine encephalitis virus in vaccinated mice. Vaccine 20 3-4 (2001) 616-622